Infugen Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 26 Year, 20 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 15.60 Cr
- Satisfied Charges ₹ 1.60 Cr
- Revenue Growth 8.25%
- Profit Growth 61.32%
- Ebitda -37.66%
- Net Worth 51.64%
- Total Assets -9.29%
About Infugen Pharma
Infugen Pharma Private Limited (IPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 04 February 1999 and has a history of 26 years. Its registered office is in Sangli, Maharashtra, India.
The Corporate was formerly known as Jeshika Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹15.60 Cr. The company has closed loans amounting to ₹1.60 Cr, as per Ministry of Corporate Affairs (MCA) records.
Bharat Bhate and Sandeep Modi serve as directors at the Company.
Company Details
- Location
Sangli, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24231PN1999PTC013295
- Company No.
013295
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Feb 1999
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
What products or services does Infugen Pharma Private Limited offer?
Infugen Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Anti Infective Drugs & Medicines, Antibiotic Injection, Cardiovascular Drugs & Medication, Anticoagulant and Antiplatelet Drugs, Anti Smoking Drugs, Anti Infective Agent.
Who are the key members and board of directors at Infugen Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bharat Bhate  | Director | 04-Feb-1999 | Current |
| Sandeep Modi | Director | 04-Feb-1999 | Current |
Financial Performance of Infugen Pharma.
Infugen Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.25% increase. The company also saw a substantial improvement in profitability, with a 61.32% increase in profit. The company's net worth Soared by an impressive increase of 51.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Infugen Pharma?
In 2023, Infugen Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Infugen Life Sciences Private LimitedBharat Bhate and Sandeep Modi are mutual person
- Medomart Private Limited
Bharat Bhate and Sandeep Modi are mutual person
Charges (Loans)
₹156.00 M
₹16.00 M
Charges Breakdown by Lending Institutions
- Others : 15.60 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Dec 2021 | Others | ₹1.35 Cr | Open |
| 28 Sep 2020 | Others | ₹6.50 Cr | Open |
| 19 Mar 2020 | Others | ₹3.50 Cr | Open |
| 20 Mar 2012 | Others | ₹4.25 Cr | Open |
| 02 Aug 2017 | Others | ₹1.10 Cr | Satisfied |
How Many Employees Work at Infugen Pharma?
Unlock and access historical data on people associated with Infugen Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Infugen Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Infugen Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.